Reduction in Total Cardiovascular Events With the PCSK9 Inhibitor Evolocumab in Patients With Cardiovascular Disease in the FOURIER Trial

被引：0
|
作者：
Murphy, Sabina A.
Pedersen, Terje R.
Gaciong, Zbigniew A.
Ceska, Richard
Ezhov, Marat V.
Connolly, Derek
Kraydashenko, Oleg
Jukema, J. Wouter
Toth, Kalman
Tikkanen, Matti J.
Im, Kyungah
Wiviott, Stephen D.
Kurtz, Christopher
Honarpour, Narimon
Giugliano, Robert P.
Keech, Anthony C.
Sever, Peter S.
Sabatine, Marc S.
机构：
来源：
CIRCULATION | 2017年 / 136卷
关键词：
LDLPCSK9;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
15100
引用
收藏
页数：1
相关论文
共 50 条
  • [31] PLASMA PCSK9 AND CARDIOVASCULAR EVENTS IN TYPE 2 DIABETES
    El Khoury, Petra
    Roussel, Ronan
    Fumeron, Frederic
    Velho, Gilberto
    Jacob, Marie-Paule
    Steg, Gabriel
    Potier, L.
    Ghaleb, Youmna
    Elbitar, Sandy
    Abifadel, Marianne
    Boileau, Catherine
    Marre, Michel
    Varret, Mathilde
    Hansel, Boris
    ATHEROSCLEROSIS, 2017, 263 : E81 - E81
  • [32] Regression of Coronary Atherosclerosis With the PCSK9 Inhibitor Evolocumab in Patients With Coronary Artery Disease and Diabetes
    King, Peta
    Puri, Rishi
    Koenig, Wolgang
    Brennan, Danielle M.
    Somaratne, Ransi
    Kassahun, Helina
    Wasserman, Scott M.
    Nissen, Steven E.
    Nicholls, Stephen J.
    CIRCULATION, 2017, 136
  • [33] PCSK9 AND INDICES OF CARDIOVASCULAR MORBIDITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE
    Dounousi, Evangelia
    Papanikolaou, Sarantis
    Tellis, Kostas
    Duni, Anila
    Pavlakou, Paraskevi
    Tatsioni, Athina
    Tselepis, Alexandros
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 : 168 - 168
  • [34] PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease
    Bittner, Vera A.
    Giugliano, Robert P.
    Brinton, Eliot A.
    Guyton, John R.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (04) : 835 - 843
  • [35] EVALUATING THE IMPACT OF PCSK9 INHIBITORS ON CARDIOVASCULAR DISEASE
    Karcher, H.
    Wiecek, W.
    Casciano, R.
    Coeytaux, E.
    Bixer, S.
    Amzal, B.
    Abenhaim, L.
    VALUE IN HEALTH, 2017, 20 (09) : A630 - A630
  • [36] Applying the FOURIER Trial amongst Real-world Cardiovascular Disease Patients: The Cardiovascular Health in Ambulatory Care Research Team (CANHEART) PCSK9 Study
    Ko, Dennis T.
    Khan, Anam M.
    Kotrri, Gynter
    Koh, Maria
    Chu, Anna
    Austin, Peter C.
    Wijeysundera, Harindra C.
    Tu, Jack V.
    CIRCULATION, 2017, 136
  • [37] A SURGICAL WINDOW-OF-OPPORTUNITY CLINICAL TRIAL EVALUATING THE PCSK9 INHIBITOR EVOLOCUMAB IN PATIENTS WITH GLIOMA
    Singh, Kirit
    Hotchkiss, Kelly
    Foster, Matthew
    Railton, Chelsea
    Blandford, Emily
    Thomas, Elizabeth
    Miller, Elizabeth S.
    Ashley, David
    Desjardins, Annick
    Friedman, Henry
    Johnson, Margaret O.
    Friedman, Allan
    Keir, Steve
    Herndon, James
    Sampson, John
    Li, Chuan-Yuan
    Fecci, Peter
    Patel, Anoop
    Khasraw, Mustafa
    NEURO-ONCOLOGY, 2023, 25
  • [38] Lipidomic profile in patients with a very high risk of atherosclerotic cardiovascular disease on PCSK9 inhibitor therapy
    Huang, Kui
    Wen, Xiao-Qin
    Ren, Ning
    Yang, Li
    Gao, Bo
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2021, 22 (02) : 461 - 467
  • [39] Lipoprotein(a) lowering and cardiovascular risk reduction by PCSK9 inhibitors
    Safarova, Maya S.
    Kullo, Iftikhar J.
    ATHEROSCLEROSIS, 2022, 361 : 30 - 31
  • [40] Erratum to: Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
    Robert S. Rosenson
    Terry A. Jacobson
    David Preiss
    Stephen C. Djedjos
    Ricardo Dent
    Ian Bridges
    Michael Miller
    Cardiovascular Drugs and Therapy, 2016, 30 : 537 - 537
12345